Table 3.
Characteristics of patients with new onset sustained atrial arrhythmias. COPD = chronic obstructive pulmonary disease, ACEi = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin-Receptor-Blocker, ARNI = Angiotensin-Receptor-Neprilysine-Inhibitor, MRA = mineralocorticoid receptor antagonist, AAD = antiarrhythmic drugs, SOFA = Sepsis-related organ failure assessment, APACHE = Acute Physiology And Chronic Health Evaluation, SAPS = Simplified Acute Physiology Score, ICU = Intensive Care Unit, ECMO = extracorporeal membrane oxygenation, NT proBNP = N-terminal pro-brain natriuretic peptide, WBC = White blood cells, GFR = glomerular filtration rate, CRP=C-reactive protein. Statistical test used: Ɨ = T-Test, x = chi-square, * = Mann-Whitney-U Test.
| Parameter | New onset sustained atrial arrhythmias |
No sustained atrial arrhythmias |
p-value | |
|---|---|---|---|---|
| N = 37 | N = 63 | |||
| Age (years) | Mean ± sd | 68.1 ± 11.4 | 59.8 ± 15.3 | p=0.005 (Ɨ) |
| Female | N (%) | 8 (21.6) | 20 (31.7) | p = 0.276 (x) |
| BMI (kg/m2) | Mean ± sd | 28.9 ± 3.9 | 30.4 ± 7.7 | p = 0.210 (Ɨ) |
| Arterial hypertension | N (%) | 24 (64.9) | 34 (54.0) | p = 0.286 (x) |
| Coronary artery disease | N (%) | 8 (21.6) | 8 (12.7) | p = 0.240 (x) |
| LVEF (%) (baseline) | Median (25–75%) | 60 (57.5–60.0) | 60 (60.0–60.0) | p = 0.522 (*) |
| COPD | N (%) | 4 (10.8) | 7 (11.1) | p = 0.963 (x) |
| Baseline medication | ||||
| Beta Blockers | N (%) | 11 (29.7) | 12 (19.0) | p = 0.220 (x) |
| Calcium Antagonists | N (%) | 8 (21.6) | 6 (9.5) | p = 0.092 (x) |
| ACEi/ARB/ARNI | N (%) | 16 (43.2) | 15 (23.8) | p=0.042 (x) |
| MRA | N (%) | 1 (2.7) | 1 (1.6) | p = 0.700 (x) |
| NOAC/OAC | N (%) | 3 (8.1) | 2 (3.2) | p = 0.274 (x) |
| Class I,III AAD | N (%) | 0 (0.0) | 0 (0.0) | |
| Severity of illness | ||||
| SOFA (baseline) | Median (25–75%) | 9.0 (5.0–11.5) | 7.0 (4.0–11.0) | p = 0.461 (*) |
| SOFA (worst) | Median (25–75%) | 14.0 (11.0–16.0) | 12.0 (9.0–15.0) | p=0.006 (*) |
| APACHE II (baseline) | Mean ± sd | 27.1 ± 9.5 | 22.4 ± 10.1 | p=0.024 (Ɨ) |
| APACHE II (worst) | Mean ± sd | 31.8 ± 9.3 | 26.2 ± 11.0 | p=0.012 (Ɨ) |
| Horowitz Index (worst) | Median (25–75%) | 93.75 (66.0–141.8) | 105.0 (76.0–136.5) | p = 0.302 (*) |
| SAPS (baseline) | Mean ± sd | 46.3 ± 14.3 | 39.8 ± 14.1 | p=0.031 (Ɨ) |
| SAPS (worst) | Mean ± sd | 62.9 ± 14.1 | 53.5 ± 16.3 | p=0.004 (Ɨ) |
| Dialysis during ICU treatment | N (%) | 28 (75.7) | 33 (52.4) | p=0.021 (x) |
| Total days ICU treatment | Median (25–75%) | 33.0 (19.5–44.5) | 17.0 (8.0–29.0) | p<0.001 (*) |
| ECMO treatment | N (%) | 8 (21.6) | 14 (22.2) | p = 0.944 (x) |
| Mechanical ventilation | N (%) | 35 (94.6) | 47 (74.6) | p=0.012 (x) |
| Catecholamine use | N (%) | 35 (94.6) | 47 (74.6) | p=0.012 (x) |
| Antibiotic use | N (%) | 33 (89.2) | 57 (90.5) | p = 0.836 (x) |
| Red blood cell transfusion | N (%) | 27 (73.0) | 33 (52.4) | p=0.042 (x) |
| Death | N (%) | 10 (27.0) | 17 (27.0) | p = 0.996 (x) |
| Laboratory findings | ||||
| Hs- Troponin (ng/l) (baseline) | Median (25–75%) | 35.0 (19.0–171.3) | 19.0 (9.0–62.5) | p = 0.054 (*) |
| Hs- Troponin (ng/l) (worst) | Median (25–75%) | 180.0 (60.3–253.3) | 39.0 (15.0–96.0) | p<0.001 (*) |
| NT proBNP (pg/ml) (baseline) | Median (25–75%) | 1711.5 (335.3–3848.25) | 767.0 (182.5–3056.5) | p = 0.102 (*) |
| NT proBNP (pg/ml) (worst) | Median (25–75%) | 6826.0 (1851.0–16,974.0) | 1651.0 (442.0–6500.0) | p=0.002 (*) |
| GFR (baseline) | Median (25–75%) | 44.0 (30.0–82.0) | 71.0 (39.0–90.0) | p=0.048 (*) |
| GFR (worst) | Median (25–75%) | 28.0 (19.0–43.5) | 39.0 (22.0–81.0) | p=0.031 (*) |
| CRP, ng/ml (baseline) | Median (25–75%) | 152.0 (55.1–290.6) | 176.0 (105.0–282.0) | p = 0.453 (*) |
| Lactate, mmol/l (baseline) | Median (25–75%) | 11.0 (9.0–17.5) | 10.5 (8.0–14.0) | p = 0.320 (*) |